is a non-narcotic analgesic, has no effect on bleeding time relative to placebo and is the only COX-2 selective NSAID ever approved in the US to demonstrate a reduced risk of gastrointestinal bleeding versus a traditional NSAID in a controlled trial.
Researchers from Germany, Finland and Canada studied ordinary painkillers or oral non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, celebrex, ibuprofen, voltaren and rofecoxib
The study claims using NSAIDs at a high dose for eight to 30 days was "particularly harmful" when people took more than 1200mg a day of ibuprofen, 750mg a day of naproxen and more than 25mg a day of rofecoxib
The highest risk was found to be in the first month of taking the pills and to those on a high daily dose - such as more than 1,200mg of ibuprofen, 750mg of naproxen and 25mg rofecoxib
For seven traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, nimesulide, and piroxicam) and the COX-2 inhibitors etoricoxib and rofecoxib
, the odds ratios for heart failure with current use ranged from 1.
57), and etoricoxib 60 mg and rofecoxib
25 mg were comparably effective.
Patients were randomised in three groups before surgery--namely a rofecoxib
group, ibuprofen group, and a placebo group--and were given their allocated analgesia and paracetamol one hour pre-operatively.
These include rofecoxib
(Vioxx), valdecoxib (Bextra), and sibutramine (Meridia).
(Merck) was introduced in 1999 as an effective, safer alternative to non-steroidal anti-inflammatory drugs for treating pain associated with osteo-arthritis.
Notable example: Data mining detected adverse cardiac effects of rofecoxib
(Vioxx) as early as 3 years before the US Food and Drug Administration withdrew that drug.
A significant increase in risk was seen after 1 week of treatment with, ibuprofen, in the first week of treatment with rofecoxib
(which has been withdrawn from the market), and after 14-30 days with celecoxib.
A new multi-year analysis of 31 trials and more than 116,000 patients taking naproxen (Aleve), ibuprofen (Advil), diclofenac (Votaren), celecoxib (Celebrex), etoricoxib (Arcoxia), lumiracoxib (Prexige) and rofecoxib
(Vioxx) was published online Jan.